Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor
Klotho Neurosciences (NASDAQ: KLTO) announces the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o is renowned for discovering the Klotho gene, known as the 'anti-aging gene,' during his research at the National Institute of Neuroscience in Tokyo. His research showed that mice lacking the Klotho gene aged faster, while those overexpressing it lived longer. The company is developing a patent-protected secreted form of Klotho (s-KL) for treating neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's disease.
Klotho Neurosciences (NASDAQ: KLTO) annuncia la nomina del Dr. Makoto Kuro-o nel suo Consiglio Consultivo Scientifico. Il Dr. Kuro-o è noto per la scoperta del gene Klotho, conosciuto come il 'gene anti-invecchiamento', durante la sua ricerca presso l'Istituto Nazionale di Neuroscienze di Tokyo. La sua ricerca ha dimostrato che i topi privi del gene Klotho invecchiavano più rapidamente, mentre quelli che lo sovraesprimevano vivevano più a lungo. L'azienda sta sviluppando una forma secreta del Klotho (s-KL) protetta da brevetto per il trattamento di malattie neurodegenerative come la SLA, l'Alzheimer e la malattia di Parkinson.
Klotho Neurosciences (NASDAQ: KLTO) anuncia el nombramiento del Dr. Makoto Kuro-o en su Consejo Asesor Científico. El Dr. Kuro-o es reconocido por descubrir el gen Klotho, conocido como el 'gen anti-envejecimiento', durante su investigación en el Instituto Nacional de Neurociencia en Tokio. Su investigación mostró que los ratones que carecen del gen Klotho envejecen más rápido, mientras que aquellos que lo sobreexpresan viven más tiempo. La compañía está desarrollando una forma secreta de Klotho (s-KL) protegida por patente para tratar enfermedades neurodegenerativas como la ELA, el Alzheimer y la enfermedad de Parkinson.
Klotho Neurosciences (NASDAQ: KLTO)는 과학 자문 위원회에 Dr. Makoto Kuro-o를 임명했다고 발표했습니다. Kuro-o 박사는 도쿄의 국립신경과학연구소에서 '노화 방지 유전자'로 알려진 Klotho 유전을 발견한 것으로 유명합니다. 그의 연구에 따르면 Klotho 유전자가 결핍된 쥐는 더 빨리 늙고, 과발현된 쥐는 더 오래 생존했습니다. 회사는 ALS, 알츠하이머병, 파킨슨병과 같은 신경퇴행성 질병 치료를 위한 특허 보호된 비밀형 Klotho(s-KL)를 개발하고 있습니다.
Klotho Neurosciences (NASDAQ: KLTO) annonce la nomination du Dr. Makoto Kuro-o à son Conseil Consultatif Scientifique. Le Dr. Kuro-o est renommé pour la découverte du gène Klotho, connu sous le nom de 'gène anti-vieillissement', au cours de ses recherches à l'Institut National de Neurosciences de Tokyo. Ses recherches ont montré que les souris dépourvues du gène Klotho vieillissaient plus rapidement, tandis que celles qui l'exprimaient en excès vivaient plus longtemps. L'entreprise développe une forme sécrétée de Klotho (s-KL) protégée par un brevet pour traiter des maladies neurodégénératives telles que la SLA, la maladie d'Alzheimer et la maladie de Parkinson.
Klotho Neurosciences (NASDAQ: KLTO) gibt die Ernennung von Dr. Makoto Kuro-o in seinen Wissenschaftlichen Beirat bekannt. Dr. Kuro-o ist bekannt für die Entdeckung des Klotho-Gens, das als 'Anti-Aging-Gen' bekannt ist, während seiner Forschung am National Institute of Neuroscience in Tokio. Seine Forschung zeigte, dass Mäuse ohne das Klotho-Gen schneller alterten, während Mäuse mit einer Überexpression länger lebten. Das Unternehmen entwickelt eine patentgeschützte sekretierte Form von Klotho (s-KL) zur Behandlung von neurodegenerativen Erkrankungen wie ALS, Alzheimer und Parkinson.
- Appointment of pioneering Klotho gene discoverer strengthens scientific expertise
- Company holds patents for secreted form of Klotho (s-KL)
- Development pipeline includes multiple major neurodegenerative diseases
- None.
Insights
The appointment of Dr. Kuro-o, the original discoverer of the Klotho gene, to KLTO's Scientific Advisory Board represents a moderate positive development but falls short of being significantly impactful for immediate investors. While his expertise and pioneering research in aging biology adds credibility to KLTO's therapeutic approach, advisory roles typically have direct impact on near-term company performance or stock value.
His involvement may accelerate the development of KLTO's secreted Klotho (s-KL) therapies for neurodegenerative diseases, but the path from research to approved treatments remains long and uncertain. The company's focus on ALS, Alzheimer's and Parkinson's disease represents large market opportunities, though success in these challenging therapeutic areas is far from guaranteed.
Discoverer of Klotho gene further strengths KLTO Scientific Advisory Board
NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board.
Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the Klotho gene, often referred to as the "anti-aging gene." While conducting groundbreaking research at the National Institute of Neuroscience in Tokyo, Dr. Kuro-o and his team identified the Klotho gene while studying mice engineered to overexpress a gene linked to premature aging. This landmark discovery revealed that Klotho plays a key role in regulating aging processes. Mice deficient in the Klotho gene exhibited accelerated aging, while those with overexpression of the gene experienced extended lifespans, positioning Klotho as a potential therapeutic target for age-related conditions.
Klotho Neurosciences’ CEO, Dr. Joseph Sinkule, warmly welcomed Dr. Kuro-o, expressing deep admiration for his pioneering contributions to aging research. "Dr. Kuro-o’s discovery of the Klotho gene revolutionized our understanding of the biology of aging. His insights will be invaluable as we work to develop our patent-protected secreted form of Klotho (s-KL) as a treatment for neurodegenerative diseases, including ALS, Alzheimer’s, and Parkinson’s disease. We are confident that his involvement will significantly accelerate our efforts to bring s-KL-based therapies to clinical trials and ultimately to patients."
In response to his appointment, Dr. Kuro-o expressed his enthusiasm: "I am honored to join the Scientific Advisory Board at Klotho Neurosciences. The innovative work being done with s-KL, the company's patented secreted form of Klotho, is truly impressive. I am excited to collaborate with the other members of the Scientific Advisory Board to advance this promising therapeutic approach."
Dr. Kuro-o’s contributions to Klotho Neurosciences will support the company’s mission to develop cutting-edge therapies that target the biological mechanisms of aging and improve the treatment of neurodegenerative diseases.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biopharmaceutical company pioneering the development of innovative, disease-modifying cell and gene therapies using a patented secreted form of the anti-aging Klotho gene (s-KL) to transform the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Eric Boyd
Investor Relations
Email: IR@klothoneuro.com
Website: www.klothoneuro.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
FAQ
What is the significance of Dr. Makoto Kuro-o joining Klotho Neurosciences (KLTO)?
What diseases is Klotho Neurosciences (KLTO) targeting with their s-KL therapy?
What was discovered about the Klotho gene in Dr. Kuro-o's research?
